Lung Cancer

David R. Gandara, MD, discusses research reflecting the capabilities of ctDNA assays to detect MRD and prognosticate adjuvant NSCLC treatment outcomes.

Erminia Massarelli, MD, PhD, MS, discusses selpercatinib and pralsetinib in treating advanced non-small cell lung cancer.

Karen L. Reckamp, MD, MS, discusses the role of amivantamab in the treatment of advanced non–small cell lung cancer.

The EMA’s CHMP has recommended the approval of amivantamab plus chemotherapy for pretreated, EGFR-mutated advanced non–small cell lung cancer.

First-line sugemalimab plus chemotherapy has been approved in Europe for metastatic non–small cell lung cancer.

Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.

Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations.

Atezolizumab administered before and following chemoradiation appeared to be safe and efficacious in unresectable stage III non–small cell lung cancer.

Should the FDA require that new trial design proposals for perioperative regimens for resectable NSCLC include adequate within trial assessment?

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of surgical resectability in patients with borderline resectable NSCLC.

Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC.

Crofelemer did not improve the incidence of diarrhea in patients with solid tumors receiving targeted therapy.

In a detailed analysis, key opinion leaders (KOLs) review the results of the DELLphi-301 Phase 2 clinical trial, assessing the efficacy of platinum-based chemotherapy in the treatment of small cell lung cancer (SCLC) and its impact on overall survival outcomes for patients enrolled in the study.

In a focused discussion, Anne Chiang, MD, PhD, explores the sequencing of later-line therapies for limited-stage small cell lung cancer (LS-SCLC), emphasizing key factors to consider when making treatment decisions for patients who have progressed on initial therapy.

The panel explores promising novel therapies in the treatment landscape, focusing on new or recently presented data at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, and share their insights on the potential impact of these therapies on future clinical practice.

Helena A. Yu, MD, examines the patient selection criteria for potentially using osimertinib monotherapy, osimertinib plus chemotherapy, or amivantamab combined with lazertinib in the first-line treatment of advanced EGFR-mutant non-small cell lung cancer.

The FDA has awarded fast track designation to the next-generation precision radiopharmaceutical therapy ABD-147 for the treatment of patients with ES-SCLC.

Key opinion leaders investigate the potential impact of redefining small cell lung cancer (SCLC) as a molecularly heterogeneous malignancy on personalized treatment strategies for SCLC subtypes with distinct therapeutic vulnerabilities, while exploring the emerging role of blood-based biomarkers in shaping the evolving treatment landscape for SCLC.

Key opinion leaders examine the PD-L1 expression and tissue tumor mutational burden (TMB) data from the CASPIAN trial, which evaluated the combination of durvalumab with platinum-etoposide for extensive-stage small cell lung cancer (ES-SCLC), weighing the potential predictive value of PD-L1 and tissue TMB in assessing progression-free survival (PFS) and objective response rate (ORR) outcomes.

Benjamin Levy, MD, initiates a discussion on the rationale behind using amivantamab and lazertinib as a first-line treatment for EGFR-mutant non-small cell lung cancer and reviews the recently presented efficacy and safety data from the MARIPOSA trial.

The panel discusses which patients with EGFR-mutant non-small cell lung cancer (NSCLC) are more likely to receive frontline treatment with either osimertinib monotherapy or the combination of osimertinib and chemotherapy, based on individual patient characteristics and preferences.

Health Canada has approved osimertinib/chemotherapy for advanced non–small cell lung cancer harboring EGFR exon 19 deletions or exon 21 L858R mutations.